Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(2)

Phase 3(1)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00202007Phase 2Completed

Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia

Role: collaborator

NCT01779401Not ApplicableCompleted

Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients

Role: collaborator

NCT00847860Phase 4Completed

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

Role: collaborator

NCT00272467Phase 4Completed

Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

Role: collaborator

NCT00202020Phase 3Completed

Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke

Role: collaborator

All 5 trials loaded